Fed’s Powell opens door to potential rate cuts at Jackson Hole
Neil Peterson, the Chief Operating Officer of Merit Medical Systems Inc. (NASDAQ:MMSI), recently sold 5,000 shares of the company’s common stock, generating a total of $525,000. The shares were sold at a price of $105 each on March 3, 2025, near the stock’s 52-week high of $111.45. According to InvestingPro analysis, MMSI currently appears overvalued, with the stock trading at a P/E ratio of 49.6x and showing high EBIT and EBITDA multiples. Following this transaction, Peterson’s direct ownership of the company’s shares stands at 28,369.
In addition to the sale, Peterson exercised stock options to acquire 5,000 shares at $54.4 per share, totaling $272,000. This transaction was part of a Rule 10b5-1 trading plan that Peterson adopted in November 2024. The exercise and subsequent sale of shares were conducted on the same day.
In other recent news, Merit Medical Systems , Inc. reported fourth-quarter earnings that exceeded expectations, with earnings per share (EPS) reaching $0.93, surpassing estimates of $0.82 and $0.83 from Oppenheimer and the Street, respectively. The company’s revenue for the quarter was $355.2 million, which also beat the anticipated $346.76 million. Merit Medical (TASE:BLWV)’s strong performance was highlighted by a 9% year-over-year increase in total revenue and a significant 67% rise in free cash flow, totaling $185 million for 2024. Despite these positive results, both Oppenheimer and Needham adjusted their price targets for Merit Medical to $116, down from $120 and $122, respectively, while maintaining Outperform and Buy ratings. Meanwhile, Raymond (NSE:RYMD) James raised its price target to $116 from $110, citing the highest-ever gross margin for the company and potential to outperform its forecasts. Merit Medical’s recent acquisitions, including Cook Medical and EndoGastric Solutions, have been performing well, contributing to the company’s growth. The company has projected revenue growth of 8-10% for 2025, with an EPS guidance that fell slightly below consensus due to changes in accounting treatment for convertible securities. Analysts from Needham and Raymond James expressed confidence in Merit Medical’s strategy, expecting continued revenue growth and margin expansion.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.